modelGlatiramerAcetate
Extends from Pharmacolibrary.Drugs.ATC.L.L03AX13.
Information
| name: | GlatiramerAcetate | |
| ATC code: | L03AX13 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Glatiramer acetate is an immunomodulatory drug used primarily for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is a synthetic mixture of polypeptides composed of four amino acids and works by modifying immune processes thought to be involved in MS. It is still approved and used today for this indication.
Pharmacokinetics
No classical pharmacokinetic parameters are available in the literature for glatiramer acetate, as it is rapidly degraded locally after subcutaneous administration and plasma concentrations are undetectable. Data represent known clinical use in adults with multiple sclerosis.
References
Scott, LJ (2013). Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS drugs 27(11) 971–988. DOI:10.1007/s40263-013-0117-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24129744
Johnston, J, & So, TY (2012). First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Drugs 72(9) 1195–1211. DOI:10.2165/11634010-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22642799
Ziemssen, T, et al., & Hohlfeld, R (2001). Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug safety 24(13) 979–990. DOI:10.2165/00002018-200124130-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11735654
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)